Evidence map›Paper›PMID 39758829›Full record

ArticleBioinformatics advances2025

Predicting CRISPR-Cas9 off-target effects in human primary cells using bidirectional LSTM with BERT embedding.

Orhan Sari, Ziying Liu, Youlian Pan, Xiaojian Shao

Abstract read
In one paragraph

Article in Bioinformatics advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. From Code to Life: The AI-Driven Revolution in Genome Editing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Orhan SariDepartment of Mining and Materials Engineering, McGill University, Montreal, QC, H3A 2B1, Canada.
Ziying LiuDigital Technologies Research Center, National Research Council Canada, Ottawa, ON, K1A 0R6, Canada.
Youlian PanDigital Technologies Research Center, National Research Council Canada, Ottawa, ON, K1A 0R6, Canada.
Xiaojian ShaoDigital Technologies Research Center, National Research Council Canada, Ottawa, ON, K1A 0R6, Canada.ORCID https://orcid.org/0000-0002-3044-621X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Motivation: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 system is a ground-breaking genome editing tool, which has revolutionized cell and gene therapies. One of the essential components involved in this system that ensures its success is the design of an optimal single-guide RNA (sgRNA) with high on-target cleavage efficiency and low off-target effects. This is challenging as many conditions need to be considered, and empirically testing every design is time-consuming and costly. Results: We present CrisprBERT, a deep learning model incorporating a Bidirectional Encoder Representations from Transformers (BERT) architecture to provide a high-dimensional embedding for paired sgRNA and DNA sequences and Bidirectional Long Short-term Memory networks for learning, to predict the off-target effects of sgRNAs utilizing only the sgRNAs and their paired DNA sequences. We proposed doublet stack encoding to capture the local energy configuration of the Cas9 binding and applied the BERT model to learn the contextual embedding of the doublet pairs. Our results showed that the new model achieved better performance than state-of-the-art deep learning models regarding single split and leave-one-sgRNA-out cross-validations as well as independent testing. Availability and implementation: The CrisprBERT is available at GitHub: https://github.com/OSsari/CrisprBERT.

Identifiers

PMID39758829
PMCPMC11696696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.